(NYSE Amex Equities : CVM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. 0.88%63.181.0%$430.38m
AMGNAmgen, Inc. -0.19%237.161.3%$414.62m
BIIBBiogen, Inc. 0.47%288.541.4%$364.69m
ILMNIllumina, Inc. 0.91%331.323.5%$326.51m
VRTXVertex Pharmaceuticals, Inc. 0.66%235.541.9%$275.17m
EXASEXACT Sciences Corp. 9.00%93.6324.0%$214.85m
REGNRegeneron Pharmaceuticals, Inc. -1.36%358.782.6%$214.32m
ITCIIntra-Cellular Therapies, Inc. -0.71%25.259.0%$172.23m
ALXNAlexion Pharmaceuticals, Inc. -1.50%111.312.0%$170.45m
INCYIncyte Corp. 0.39%78.962.5%$135.65m
SRPTSarepta Therapeutics, Inc. -1.68%120.9314.6%$130.81m
AAgilent Technologies, Inc. 0.67%90.211.6%$120.85m
BMRNBioMarin Pharmaceutical, Inc. 0.57%88.054.3%$106.77m
BLUEbluebird bio, Inc. -2.47%93.4514.2%$92.91m
SGENSeattle Genetics, Inc. 1.79%110.626.1%$91.95m

Company Profile

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.